Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00380965
Status:
COMPLETED
Last Update Posted:
2008-02-15
First Post:
2006-09-25
Brief Title:
Evaluation of the Efficacy of Cesamet for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
Sponsor:
NEMA Research Inc
Organization:
NEMA Research Inc
Study Overview
Official Title:
A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to evaluate the safety and efficacy of Cesamet in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer
Detailed Description:
To determine the safety and efficacy of Cesamet in the symptomatic treatment of chemotherapy-induced neuropathic pain
This is a phase IV multicenter open label of Cesamet at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain This study has two phases A pretreatment phase and a treatment phase
This is a phase IV multicenter open label of Cesamet at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain This study has two phases A pretreatment phase and a treatment phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None